" class="no-js "lang="en-US"> Ochre Bio Appoints Eliot Forster as Chairperson of its Board
Tuesday, April 23, 2024

Ochre Bio Appoints Eliot Forster, Ph.D. as Chairperson of its Board of Directors

Ochre Bio, an innovator in chronic liver disease medicine development, today announced the appointment of Eliot Forster, PhD as Chairperson of the Board of Directors. With decades of experience in pharmaceutical and biotechnology industries, cofounding and leading several companies Dr. Forster has successfully raised more than $550M in equity financing, having previously served as CEO at F-Star Therapeutics CEO and Immunocore Ltd and Chairperson of Avacta PLC.

The news follows the recent appointment of Chinwe Ukomadu, MD, PhD as an Observer on its Board of Directors, and David Coughlan, PhD as VP of Translational Development, as Ochre Bio continues to strengthen its leadership.

“Eliot’s broad experience is highly relevant for Ochre’s next phase and we couldn’t be more pleased to announce his appointment as Chairman of our Board of Directors,” said Jack O’Meara, CEO of Ochre Bio. “Eliot joins us at a pivotal point in Ochre’s journey, as we begin the transition from a discovery-stage to a clinical-stage company, and we look forward to leveraging his extensive leadership experience towards the development of impactful medicines for liver disease patients.”

“Progressing an advanced therapy from idea to clinic is one of the most challenging things to achieve,” said Quin Wills, CSO of Ochre Bio. “Eliot is one of those rare individuals who has done this multiple times. We are humbled to have him as part of the Ochre team.”

Eliot Forster said, “I am honoured to join Ochre Bio as Chairperson. The company is founded on a fully differentiated scientific strategy to uncover and validate fundamental disease pathways in the liver. Using ex vivo human-liver models, Ochre has a unique approach to bring hope to patients where therapeutic options are sorely lacking. I look forward to working with the management team to build a great company and a pipeline of innovative medicines for those suffering from liver and liver-mediated diseases.”

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more